Folic acid (FA)-conjugated mesoporous silica nanoparticles combined with MRP-1 siRNA improves the suppressive effects of myricetin on non-small cell lung cancer (NSCLC)
Non-small cell lung cancer (NSCLC) is a common diagnosed cancer disease worldwide and its management remains a challenge. Synergistic cancer therapeutic strategy is interesting for multiple advantages, such as excellent targeting accuracy, low side effects, and promoted therapeutic efficiency. In th...
Main Authors: | , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2020-05-01
|
Series: | Biomedicine & Pharmacotherapy |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S0753332219351844 |
id |
doaj-539a3bfc5b9243f6a2109bddb68f8076 |
---|---|
record_format |
Article |
spelling |
doaj-539a3bfc5b9243f6a2109bddb68f80762021-05-20T07:39:16ZengElsevierBiomedicine & Pharmacotherapy0753-33222020-05-01125109561Folic acid (FA)-conjugated mesoporous silica nanoparticles combined with MRP-1 siRNA improves the suppressive effects of myricetin on non-small cell lung cancer (NSCLC)Yinxue Song0Bin Zhou1Xiangyang Du2Yong Wang3Jie Zhang4Yanqiu Ai5Zongjiang Xia6Gaofeng Zhao7Department of Emergency, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, 710061, ChinaDepartment of Thoracic Surgery, Shanxian Central Hospital, Shanxian, Shandong, 274300, ChinaDepartment of Respiration, Shandong Provincial Third Hospital, Jinan, Shandong, 250031, China; Corresponding authors.R&D Center of Zhengzhou Bio-Medicinal Institute, Zhengzhou, 450052, China; Corresponding authors.R&D Center of Zhengzhou Bio-Medicinal Institute, Zhengzhou, 450052, ChinaR&D Center of Zhengzhou Bio-Medicinal Institute, Zhengzhou, 450052, ChinaDepartment of New Drugs Development, Shanghai Genecure Pharmaceutical Institute, Shanghai, 200040, ChinaDepartment of New Drugs Development, Shanghai Genecure Pharmaceutical Institute, Shanghai, 200040, ChinaNon-small cell lung cancer (NSCLC) is a common diagnosed cancer disease worldwide and its management remains a challenge. Synergistic cancer therapeutic strategy is interesting for multiple advantages, such as excellent targeting accuracy, low side effects, and promoted therapeutic efficiency. In the present study, myricetin (Myr)-loaded mesoporous silica nanoparticles (MSN) combined with multidrug resistance protein (MRP-1) siRNA was prepared. The surface of the synthesized nanoparticles was modified with folic acid (FA) to promote the therapeutic efficiency of Myr for the treatment of NSCLC. The collected particles were nano-sized and showed a sustained release of Myr in the physiological conditions. FA-conjugated nanoformulations displayed a significant uptake in lung cancer cells compared with that of the non-targeted nanoparticles. The in vitro drug release results suggested a sustained release in FA-conjugated MSN with Myr and MRP-1 nanoparticles compared to the free Myr and MSN combined with MRP-1/Myr. Treatments with FA-conjugated MSN combined with Myr and MRP-1 markedly reduced the cell viability of lung cancer cell lines, including A549 and NCI-H1299, which was accompanied with the decreased number of colony formation. In addition, FA-conjugated MSN loaded with Myr and MRP-1 significantly induced apoptosis in lung cancer cells, along with up-regulated expression levels of cleaved Caspase-3 and PARP. In vivo fluorescence results demonstrated that FA-conjugated MSN with Myr and MRP-1 nanoparticles could specifically accumulate at tumor sites. Compared with free Myr and MSN combined with MRP-1/Myr nanoparticles, FA-conjugated MSN loaded with Myr and MRP-1 nanoparticles could more effectively suppress tumor growth with little side effects. Overall, FA-conjugated nanoparticulate system could provide a novel and effective platform for the treatment of NSCLC.http://www.sciencedirect.com/science/article/pii/S0753332219351844NSCLCMyricetinMesoporous silica nanoparticlesMRP-1Folic acid |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Yinxue Song Bin Zhou Xiangyang Du Yong Wang Jie Zhang Yanqiu Ai Zongjiang Xia Gaofeng Zhao |
spellingShingle |
Yinxue Song Bin Zhou Xiangyang Du Yong Wang Jie Zhang Yanqiu Ai Zongjiang Xia Gaofeng Zhao Folic acid (FA)-conjugated mesoporous silica nanoparticles combined with MRP-1 siRNA improves the suppressive effects of myricetin on non-small cell lung cancer (NSCLC) Biomedicine & Pharmacotherapy NSCLC Myricetin Mesoporous silica nanoparticles MRP-1 Folic acid |
author_facet |
Yinxue Song Bin Zhou Xiangyang Du Yong Wang Jie Zhang Yanqiu Ai Zongjiang Xia Gaofeng Zhao |
author_sort |
Yinxue Song |
title |
Folic acid (FA)-conjugated mesoporous silica nanoparticles combined with MRP-1 siRNA improves the suppressive effects of myricetin on non-small cell lung cancer (NSCLC) |
title_short |
Folic acid (FA)-conjugated mesoporous silica nanoparticles combined with MRP-1 siRNA improves the suppressive effects of myricetin on non-small cell lung cancer (NSCLC) |
title_full |
Folic acid (FA)-conjugated mesoporous silica nanoparticles combined with MRP-1 siRNA improves the suppressive effects of myricetin on non-small cell lung cancer (NSCLC) |
title_fullStr |
Folic acid (FA)-conjugated mesoporous silica nanoparticles combined with MRP-1 siRNA improves the suppressive effects of myricetin on non-small cell lung cancer (NSCLC) |
title_full_unstemmed |
Folic acid (FA)-conjugated mesoporous silica nanoparticles combined with MRP-1 siRNA improves the suppressive effects of myricetin on non-small cell lung cancer (NSCLC) |
title_sort |
folic acid (fa)-conjugated mesoporous silica nanoparticles combined with mrp-1 sirna improves the suppressive effects of myricetin on non-small cell lung cancer (nsclc) |
publisher |
Elsevier |
series |
Biomedicine & Pharmacotherapy |
issn |
0753-3322 |
publishDate |
2020-05-01 |
description |
Non-small cell lung cancer (NSCLC) is a common diagnosed cancer disease worldwide and its management remains a challenge. Synergistic cancer therapeutic strategy is interesting for multiple advantages, such as excellent targeting accuracy, low side effects, and promoted therapeutic efficiency. In the present study, myricetin (Myr)-loaded mesoporous silica nanoparticles (MSN) combined with multidrug resistance protein (MRP-1) siRNA was prepared. The surface of the synthesized nanoparticles was modified with folic acid (FA) to promote the therapeutic efficiency of Myr for the treatment of NSCLC. The collected particles were nano-sized and showed a sustained release of Myr in the physiological conditions. FA-conjugated nanoformulations displayed a significant uptake in lung cancer cells compared with that of the non-targeted nanoparticles. The in vitro drug release results suggested a sustained release in FA-conjugated MSN with Myr and MRP-1 nanoparticles compared to the free Myr and MSN combined with MRP-1/Myr. Treatments with FA-conjugated MSN combined with Myr and MRP-1 markedly reduced the cell viability of lung cancer cell lines, including A549 and NCI-H1299, which was accompanied with the decreased number of colony formation. In addition, FA-conjugated MSN loaded with Myr and MRP-1 significantly induced apoptosis in lung cancer cells, along with up-regulated expression levels of cleaved Caspase-3 and PARP. In vivo fluorescence results demonstrated that FA-conjugated MSN with Myr and MRP-1 nanoparticles could specifically accumulate at tumor sites. Compared with free Myr and MSN combined with MRP-1/Myr nanoparticles, FA-conjugated MSN loaded with Myr and MRP-1 nanoparticles could more effectively suppress tumor growth with little side effects. Overall, FA-conjugated nanoparticulate system could provide a novel and effective platform for the treatment of NSCLC. |
topic |
NSCLC Myricetin Mesoporous silica nanoparticles MRP-1 Folic acid |
url |
http://www.sciencedirect.com/science/article/pii/S0753332219351844 |
work_keys_str_mv |
AT yinxuesong folicacidfaconjugatedmesoporoussilicananoparticlescombinedwithmrp1sirnaimprovesthesuppressiveeffectsofmyricetinonnonsmallcelllungcancernsclc AT binzhou folicacidfaconjugatedmesoporoussilicananoparticlescombinedwithmrp1sirnaimprovesthesuppressiveeffectsofmyricetinonnonsmallcelllungcancernsclc AT xiangyangdu folicacidfaconjugatedmesoporoussilicananoparticlescombinedwithmrp1sirnaimprovesthesuppressiveeffectsofmyricetinonnonsmallcelllungcancernsclc AT yongwang folicacidfaconjugatedmesoporoussilicananoparticlescombinedwithmrp1sirnaimprovesthesuppressiveeffectsofmyricetinonnonsmallcelllungcancernsclc AT jiezhang folicacidfaconjugatedmesoporoussilicananoparticlescombinedwithmrp1sirnaimprovesthesuppressiveeffectsofmyricetinonnonsmallcelllungcancernsclc AT yanqiuai folicacidfaconjugatedmesoporoussilicananoparticlescombinedwithmrp1sirnaimprovesthesuppressiveeffectsofmyricetinonnonsmallcelllungcancernsclc AT zongjiangxia folicacidfaconjugatedmesoporoussilicananoparticlescombinedwithmrp1sirnaimprovesthesuppressiveeffectsofmyricetinonnonsmallcelllungcancernsclc AT gaofengzhao folicacidfaconjugatedmesoporoussilicananoparticlescombinedwithmrp1sirnaimprovesthesuppressiveeffectsofmyricetinonnonsmallcelllungcancernsclc |
_version_ |
1721435210176790528 |